Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)7.19
  • Today's Change0.13 / 1.84%
  • Shares traded8.60m
  • 1 Year change+37.48%
  • Beta0.8683
Data delayed at least 15 minutes, as of Mar 05 2026 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Grand Pharmaceutical Group Ltd is an investment holding company mainly engaged in the pharmaceutical business. The Company is mainly engaged in the manufacture and sale of pharmaceutical preparations and medical devices. The Company is also engaged in the manufacture and sale of biotechnology products, health products, specialised pharmaceutical raw materials and other products. The Company's main products include nuclear medicine anti-tumor diagnosis and treatment and cardiovascular and cerebrovascular interventional diagnosis and treatment technology products.

  • Revenue in HKD (TTM)11.70bn
  • Net income in HKD2.08bn
  • Incorporated1995
  • Employees12.44k
  • Location
    Grand Pharmaceutical Group LtdUnits 3302The Center, 99 Queen's Road Central Hong KongHKG
  • Phone+852 28663718
  • Fax+852 28662521
  • Websitehttps://www.grandpharma.cn/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Vigonvita Life Sciences Co Ltd-100.00bn-100.00bn16.22bn---------------------------------------------------94.07---1,848.73------
HUTCHMED (China) Ltd4.70bn3.64bn18.18bn1.78k4.991.894.863.874.184.185.3811.000.39667.093.862,595,067.0030.79-9.5540.72-13.7744.1539.8477.64-20.324.51--0.07---24.8025.20-62.56--15.93--
Ab&B Bio Tech Co Ltd JS366.20m-253.85m20.07bn583.00--527.06--54.79-0.6452-0.64520.93080.0968----------------67.29---69.32--0.3162-9.490.9646--397.65--39.09------
Shanghai Henlius Biotech Inc6.56bn932.37m22.18bn3.54k37.379.0415.733.381.721.7212.077.090.53861.735.861,865,728.007.66-3.2113.85-5.7675.7772.5014.22-7.870.504610.470.5185--6.11128.9850.26--10.83--
PegBio Co Ltd-100.00bn-100.00bn23.43bn58.00--80.08----------0.748------------------------3.07--0.2439-------1.49------
Sunshine Lake Pharma Co Ltd3.82bn-447.86m23.77bn6.53k--53.7719,897.926.23-0.7766-0.77666.620.7673------582,760.90--------73.62---12.86--0.7739-0.75910.5111---37.06---212.17------
The United Laboratories Intl. Hldgs Ltd.15.95bn3.46bn24.17bn17.40k6.421.265.801.521.911.918.789.690.53972.895.97938,276.0011.719.3717.4614.5447.2444.3321.7015.061.60--0.247226.010.138710.39-1.5432.8937.2545.96
Grand Pharmaceutical Group Ltd11.70bn2.08bn25.06bn12.44k11.881.449.672.140.59430.59433.354.900.45573.663.88976,472.807.9910.4010.8114.2457.6461.0417.5322.800.9872--0.210729.1210.5912.0631.3016.490.739822.05
Duality Biotherapeutics Inc2.45bn-3.20bn25.69bn191.00--7.62--10.46-36.94-36.9428.6837.42------14,440,700.00--------37.13---130.43------0.0228--8.66---193.82------
China Resources Pharmaceutical Group Ltd295.15bn3.19bn27.52bn86.00k8.620.48692.110.09320.50830.508346.989.000.94345.572.414,059,896.002.863.1410.2811.7815.8115.593.033.021.1211.260.424822.385.307.41-13.062.9512.427.30
Xuanzhu Biopharmaceutical Co Ltd36.15m-629.31m28.25bn197.00--29.53--781.65-1.21-1.210.06981.85----------------41.02---1,740.97--1.10--0.0013--103,672.40---85.13------
Simcere Pharmaceutical Group Ltd8.04bn995.57m29.41bn6.82k27.993.4321.103.660.40470.40473.263.310.58452.202.811,220,890.007.248.749.9312.4281.0078.5312.3915.601.574.720.145344.120.41485.672.57-6.098.48--
China Medical System Holdings Ltd8.89bn1.87bn31.10bn6.10k16.511.6214.413.500.77220.77223.687.890.42393.146.121,447,713.008.8516.359.8818.7071.4775.0320.8832.205.28--0.041740.16-6.794.22-32.54-3.756.01-2.60
Data as of Mar 05 2026. Currency figures normalised to Grand Pharmaceutical Group Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

5.36%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 04 Feb 202641.79m1.18%
GF Fund Management Co., Ltd.as of 30 Jun 202530.63m0.86%
Dimensional Fund Advisors LPas of 05 Feb 202626.99m0.76%
Ping An Fund Management Co., Ltd.as of 30 Jun 202519.85m0.56%
BlackRock Fund Advisorsas of 06 Feb 202617.01m0.48%
China Universal Asset Management Co., Ltd.as of 30 Jun 202515.80m0.45%
Bosera Asset Management Co., Ltd.as of 30 Jun 202512.55m0.35%
ICBC UBS Asset Management Co. Ltd.as of 30 Jun 20258.92m0.25%
Purekind Fund Management Co., Ltd.as of 30 Jun 20258.55m0.24%
Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt)as of 30 Jun 20258.03m0.23%
More ▼
Data from 30 Jun 2025 - 20 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.